Biopharma · FDA Approvals · Stock
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) …
Assets on file: rintatolimod
Dated catalysts for AIM, including recently decided ones.
Every first-hand event for AIM, newest first.
AIM ImmunoTech Outlines Ampligen + daraxonrasib Opportunity; DURIPANC Phase 2 Topline in Q1 2027
This investor presentation is the first public announcement of Phase 2 DURIPANC topline clinical-benefit-rate results expected in Q1 2027 and additional OS/PFS/immune analyses in Q3 2027 for Ampligen plus durvalumab maintenance after FOLFIRINOX in metastatic pancreatic cancer. It also proposes future investigation of Ampligen to extend benefit of RAS-targeted agents such as daraxonrasib but does not report new clinical data or regulatory actions.
rintatolimod · NCT05927142 registry update
status: RECRUITING → ACTIVE_NOT_RECRUITING; primary_completion: 2026-04 → 2026-12
AIM ImmunoTech posts KOL segment on Ampligen pancreatic-cancer data
The company released an on-demand Virtual Investor KOL segment featuring Prof. Casper van Eijck discussing Ampligen’s mechanism and clinical data. Interim Phase 2 DURIPANC readout (Ampligen + durvalumab) and full enrollment are now expected in June 2026.
Companies in the same sector closest to AIM in market value.